In the midst of this truly positive news for CLDX and rGBM sufferers alike, I would be remiss if I failed to mention another company also in a pivotal Ph III trial, whose therapy may in the not too distant future be granted approval for ND-GBM in the US and EU (they are currently not seeking approval for recurrent GBM). That company is Northwest Biotherapeutics (NASDAQ:NWBO).
People that have read any of my previous articles know of my stance on this company: it's very bullish. No reason to dance around that reality. However, the two may be able to coexist peacefully in the GBM space after all (at least in terms of their potential future balance sheets).
Rindo's target population for ND-GBM is around 25%, and a little less for recurrent cases. However, EGFRvIII is also expressed in 78% of breast carcinomas, 73% of ovarian carcinomas, 42% of head and neck squamous cell carcinomas, and 39% of non-small-cell lung cancers. The market for Rindo extends past GBM, and upon approval management will no doubt conduct trials to obtain label extension of their biologic into the above indications as well, expressing a truly massive market share.
All told, this is why they are currently undervalued at around a $1.3B market cap; the now almost certain AA of Rindo for rGBM, which also portends achieving approval for ND-GBM; the value in Rindo to treat the above various indications, and the value in Glemba for TNBC and the up-and-comer Varli.
However, if we look at the potential in NWBO relative to their market cap ($340mm), and consider that Evaluate Pharma ranks their potential WW NPV at $5.7B, with estimated annual sales of DCVax-L for ND-GBM at $2.1B (these figures would nearly double with the addition of recurrent GBM sales), and also consider the recently shown preliminary efficacy found with DCVax-Direct, a very great upside potential also lies with NWBO, despite their less attractive cash position. I've gone over other specifics on them here and here.
Though regarding competition with CLDX, a recent abstract and presentation at the SNO showed that DCVax-L is less effective in the EGFRvIII+ patients that Rindo targets. Therefore it is likely that DCVax-L, should it find approval, will not infringe upon the marketability of Rindopepimut. They may end up splitting this market with 75% going to NWBO and 25% to CLDX. And considering the urgent need in this indication with essentially no effective therapies to prolong patients' survival, deep market penetration is probable.
Portable decontamination units. infection containment units, Hazmat suits. Air filtration systems, Protective hoods, respirators, gloves, boots, face protectors, portable triage centers, 220 million backlog, blue light sanitation units, government contracts and only 8 million share float.
it went as high as 97, so were can CYBR run too? 3x as much?
Comments by President, Erwin of IBIO.
Giroir said the Texas center "is very familiar" with plant-based antibody production. If it wins a government contract for ZMapp production, it would likely tap Caliber Biotherapeutics, which specializes in tobacco-plant-based drug production and shares the Texas campus, as a subcontractor
Adam Havey, president of Emergent's biodefense division, said the company has been in discussions with plant-based manufacturers to develop a response to the task order.
IBIO going to $20
2. Stock seems to be gathering support 3. Powers can accept a partnership at anytime if she feels she needs it 4.german revenues to start and grow into 2015+ 5. CELG and ROCHE bought into phase 1 immunotherapy companies and show me this IS the future for consolidation. 6. Unmet medical needs and probable fast track designation 7. Late in this game to start a new short position 8. Overseas interest that doesn't care about US shorts 9. Amazing trials and personal stories just starting to be heard. 10, waking up to a major business publication touting NWBO (Forbes, Business Week, Fortune, Washington Post, Bloomberg etc)
And more is coming in next 6 months bigger and better!
is spending a BILLION dollars for their phase1 IMMUNOTHERAPY drug. NWBO to $30 imo.